AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15311643 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic levels drawn from a peripheral vein
Number of subjects: 0
Study 10907964 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 1 microg/kg
Number of subjects: 34
Study 10907964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8884056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (6-10 cigarettes/day)
Number of subjects: 530
Study 8884056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (more than 10 cigarettes/day)
Number of subjects: 530
Study 8884056 — intervention group
Group type: EXPERIMENTAL
Intervention: Low maternal weight gain
Number of subjects: 530
Study 8884056 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged vaginal bleeding
Number of subjects: 530
Study 8884056 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital status - single
Number of subjects: 530
Study 8884056 — intervention group
Group type: EXPERIMENTAL
Intervention: First contact with physician after 12 weeks of pregnancy
Number of subjects: 530
Study 8884056 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent job loss
Number of subjects: 530
Study 1303482 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 78
Study 1303482 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 78
Study 1303482 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg and 10 mg)
Number of subjects: 78
Study 4074113 — intervention group
Group type: EXPERIMENTAL
Intervention: Insight-oriented therapy
Number of subjects: 41
Study 4074113 — intervention group
Group type: EXPERIMENTAL
Intervention: Current events group
Number of subjects: 41
Study 4074113 — intervention group
Group type: COMPARATOR
Intervention: Control group (nontreatment)
Number of subjects: 41
Study 4074113 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy group (including insight-oriented and current events)
Number of subjects: 41
Study 3650325 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual rolling of the nipple
Number of subjects: 54
Study 3650325 — intervention group
Group type: COMPARATOR
Intervention: Application of moist, hot pads to the breast before stimulation
Number of subjects: 54
Study 30762087 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute ACL reconstruction (within 8 days)
Number of subjects: 70
Study 30762087 — intervention group
Group type: COMPARATOR
Intervention: Delayed ACL reconstruction (6-10 weeks)
Number of subjects: 70
Study 28748492 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate (CaP) hybridized tendon grafts
Number of subjects: 73
Study 28748492 — intervention group
Group type: COMPARATOR
Intervention: Conventional tendon grafts
Number of subjects: 73
Study 28116430 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential periodontal treatment + routine maintenance therapy (Group A)
Number of subjects: 76
Study 28116430 — intervention group
Group type: COMPARATOR
Intervention: Routine maintenance therapy (Group B)
Number of subjects: 76
Study 28116430 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential periodontal treatment (Group C)
Number of subjects: 76
Study 24403492 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous radiochemotherapy (S‐RC) with cisplatin
Number of subjects: 72
Study 24403492 — intervention group
Group type: COMPARATOR
Intervention: Systemic paclitaxel and carboplatin followed by percutaneous radiation (PC‐R)
Number of subjects: 72
Study 24403492 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score for early relapse (calculated using values of VEGFA and TIMP2)
Number of subjects: 72
Study 22938760 — intervention group
Group type: EXPERIMENTAL
Intervention: RLAI (long-acting injectable risperidone)
Number of subjects: 37
Study 22938760 — intervention group
Group type: COMPARATOR
Intervention: Oral antipsychotic treatment
Number of subjects: 37
Study 20685725 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stretching (n=32)
Number of subjects: 100
Study 20685725 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive stretching (n=35)
Number of subjects: 100
Study 20685725 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation stretching (n=33)
Number of subjects: 100
Study 20685725 — intervention group
Group type: COMPARATOR
Intervention: All groups (active, passive, proprioceptive)
Number of subjects: 100
Study 18294663 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0
Study 18294663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15993860 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 90
Study 15993860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 14690802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention group
Number of subjects: 34
Study 14690802 — intervention group
Group type: COMPARATOR
Intervention: Control group (didactic presentations, no formal memory training)
Number of subjects: 34
Study 10847570 — intervention group
Group type: EXPERIMENTAL
Intervention: SXCT imaging and plantar pressure analysis in diabetic foot
Number of subjects: 2
Study 10847570 — intervention group
Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 2
Study 9184280 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial approach
Number of subjects: 150
Study 9184280 — intervention group
Group type: COMPARATOR
Intervention: Femoral approach
Number of subjects: 150
Study 9184280 — intervention group
Group type: COMPARATOR
Intervention: Radial approach
Number of subjects: 150
Study 1337708 — intervention group
Group type: EXPERIMENTAL
Intervention: Estraderm TTS, a 17 beta‐estradiol, administered for 11 weeks (3 cycles of 3 weeks treatment followed by 1 week therapy-free)
Number of subjects: 84
Study 1337708 — intervention group
Group type: COMPARATOR
Intervention: Premarin, consisting of conjugated estrogens, administered for 11 weeks (3 cycles of 3 weeks treatment followed by 1 week therapy-free)
Number of subjects: 84
Study 3090962 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase 2000 U/kg/h for 24 hours with heparin (Group I: 18 patients)
Number of subjects: 77
Study 3090962 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase 4500 U/kg/h for 12 hours without heparin (Group II: 47 patients)
Number of subjects: 77
Study 3090962 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase 200000 U over 10 hours (Group III: 12 patients)
Number of subjects: 77
Study 3090962 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose urokinase group (Group II)
Number of subjects: 77
Study 3090962 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis repeated in patients with incomplete results or a Miller index of over 13 points
Number of subjects: 77
Study 3090962 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated lysis of pulmonary embolism
Number of subjects: 77
Study 30654726 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice conditions that enhance expectancies for future performance and support learners' autonomy
Number of subjects: 0
Study 28857618 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Heart-Walk intervention
Number of subjects: 132
Study 28857618 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study 26486585 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised physiotherapy (10 sessions)
Number of subjects: 300
Study 26486585 — intervention group
Group type: COMPARATOR
Intervention: Advice alone (2 sessions)
Number of subjects: 300
Study 24861836 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniosacral therapy (one-time intervention)
Number of subjects: 31
Study 24861836 — intervention group
Group type: COMPARATOR
Intervention: Control (defined rest period)
Number of subjects: 31
Study 22699671 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable partial dental prostheses (RPDPs) for molar replacement
Number of subjects: 215
Study 22699671 — intervention group
Group type: COMPARATOR
Intervention: No replacement (SDA)
Number of subjects: 215
Study 19841157 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium gel 1% (16 g gel applied as 4 g to 1 knee 4 times daily)
Number of subjects: 40
Study 19841157 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium gel 1% (48 g gel applied as 4 g per knee 4 times daily to 2 knees plus 2 g gel per hand applied 4 times daily to 2 hands)
Number of subjects: 40
Study 19841157 — intervention group
Group type: COMPARATOR
Intervention: Oral diclofenac sodium (150 mg oral diclofenac applied as 50-mg tablets 3 times daily)
Number of subjects: 40
Study 19841157 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium gel 1%
Number of subjects: 40
Study 19841157 — intervention group
Group type: COMPARATOR
Intervention: Oral diclofenac sodium
Number of subjects: 40
Study 17658120 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary fractionated white bean extract (1000 mg, twice a day before meals)
Number of subjects: 25
Study 17658120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to the active group)
Number of subjects: 25
Study 17658120 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary fractionated white bean extract (in high carbohydrate intake tertile)
Number of subjects: 25
Study 17658120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in high carbohydrate intake tertile)
Number of subjects: 25
Study 16056134 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar faces at threshold and suprathreshold mosaic levels
Number of subjects: 0
Study 16056134 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar faces at threshold and suprathreshold mosaic levels
Number of subjects: 0
Study 16056134 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar faces at threshold level
Number of subjects: 0
Study 16056134 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar faces at threshold level
Number of subjects: 0
Study 16056134 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosaic levels (subthreshold, threshold, suprathreshold)
Number of subjects: 0
Study 11886696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant Imagery (PI)
Number of subjects: 55
Study 11886696 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Imagery (AI)
Number of subjects: 55
Study 11886696 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 55
Study 11886696 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 55
Study 11886696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 11048457 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (8 mg in 4 mL i.v.)
Number of subjects: 92
Study 11048457 — intervention group
Group type: COMPARATOR
Intervention: placebo (4 mL saline i.v.)
Number of subjects: 92
Study 8750569 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem, 60 mg twice a day for 30 days
Number of subjects: 22
Study 8750569 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 22
Study 8750569 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem with propylthiouracil, 100 mg three times a day for the last 20 days
Number of subjects: 22
Study 1410358 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic gadolinium-enhanced FLASH images
Number of subjects: 137
Study 1410358 — intervention group
Group type: COMPARATOR
Intervention: Contrast material-enhanced CT scans
Number of subjects: 137
Study 4008675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramiracetam 400 mg
Number of subjects: 12
Study 4008675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramiracetam 800 mg
Number of subjects: 12
Study 4008675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramiracetam 1200 mg
Number of subjects: 12
Study 4008675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramiracetam 1600 mg
Number of subjects: 12
Study 4008675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30582717 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam
Number of subjects: 36
Study 30582717 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% cream
Number of subjects: 36
Study 30582717 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate 0.05% ointment
Number of subjects: 36
Study 30582717 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate 0.1% cream
Number of subjects: 36
Study 30582717 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone-17-butyrate 0.1% ointment
Number of subjects: 36
Study 30582717 — intervention group
Group type: COMPARATOR
Intervention: Foam vehicle
Number of subjects: 36
Study 28852318 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiangsha Liujunzi granules
Number of subjects: 216
Study 28852318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 26700287 — intervention group
Group type: EXPERIMENTAL
Intervention: McGRATH MAC videolaryngoscope
Number of subjects: 370
Study 26700287 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 370
Study 26700287 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 370
Study 23630307 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 149
Study 23630307 — intervention group
Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 149
Study 21253972 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise for one hour
Number of subjects: 8
Study 21253972 — intervention group
Group type: COMPARATOR
Intervention: Control trial of one hour rest
Number of subjects: 8
Study 19092238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin infusion (50 IU insulin in 50 ml 0.9% saline solution applied intravenously via a perfusor pump)
Number of subjects: 40
Study 19092238 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (insulin subcutaneously if concentrations were above 11.10 mmol/l)
Number of subjects: 40
Study 16841603 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% hydrogen peroxide with 5% potassium nitrate (FKD, Kin Lab)
Number of subjects: 16
Study 16841603 — intervention group
Group type: COMPARATOR
Intervention: 10% carbamide peroxide (Opalescence, Ultradent)
Number of subjects: 16
Study 12630984 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily for 9 days
Number of subjects: 12
Study 12630984 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 9 days
Number of subjects: 12
Study 10865091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 159
Study 10865091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 10865091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine (after placebo)
Number of subjects: 159
Study 9427885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle counseling aimed at partially replacing saturated fat with mono- and polyunsaturated fat.
Number of subjects: 553
Study 9427885 — intervention group
Group type: COMPARATOR
Intervention: Breast milk or formula (control group).
Number of subjects: 553
Study 9427885 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein E phenotype.
Number of subjects: 553
Study 8503554 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 micrograms)
Number of subjects: 12
Study 8503554 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 12
Study 8503554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3504725 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal synthetic salmon calcitonin (SSCT) 200 IU
Number of subjects: 9
Study 3504725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) injection of synthetic salmon calcitonin (SSCT) 80 IU
Number of subjects: 9
Study 3504725 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 9
Study 29067749 — intervention group
Group type: EXPERIMENTAL
Intervention: RPSS + tDCS
Number of subjects: 22
Study 29067749 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS alone
Number of subjects: 22
Study 29067749 — intervention group
Group type: EXPERIMENTAL
Intervention: RPSS alone
Number of subjects: 22
Study 29067749 — intervention group
Group type: COMPARATOR
Intervention: Sham RPSS + tDCS
Number of subjects: 22
Study 29067749 — intervention group
Group type: EXPERIMENTAL
Intervention: Grasp force of the paretic limb
Number of subjects: 22
Study 29067749 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM of wrist extension of the nonparetic limb
Number of subjects: 22
Study 29067749 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM of wrist flexion, grasp, pinch strength of the paretic and nonparetic upper limbs
Number of subjects: 22
Study 29067749 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM of wrist extension of the nonparetic wrist
Number of subjects: 22
Study 29384933 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscopic guidance in the left lateral position (Group L)
Number of subjects: 120
Study 29384933 — intervention group
Group type: COMPARATOR
Intervention: Video laryngoscopic guidance in the supine position (Group S)
Number of subjects: 120
Study 26386803 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 405
Study 26386803 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 405
Study 23035781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 595
Study 23035781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 595
Study 23035781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 595
Study 20853007 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (25,000 U for infants below 1 year of age and 50,000 U for older children)
Number of subjects: 50
Study 20853007 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone for 10 days followed by oral cephalexin for 3 months (Control)
Number of subjects: 50
Study 18367613 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic prednisone treatment (7.5 +/- 0.8 mg)
Number of subjects: 24
Study 18367613 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute prednisone administration 1 hour before retention testing
Number of subjects: 24
Study 18367613 — intervention group
Group type: COMPARATOR
Intervention: Control group (without glucocorticoids)
Number of subjects: 24
Study 16553274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fomitella fraxinea-derived lectin (FFrL)
Number of subjects: 0
Study 16553274 — intervention group
Group type: COMPARATOR
Intervention: Control saline injection
Number of subjects: 0
Study 12669752 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention allocation to one object for 100-150 ms before shifting to the next object.
Number of subjects: 0
Study 12669752 — intervention group
Group type: EXPERIMENTAL
Intervention: N2pc wave as a continuous measure of attention allocation.
Number of subjects: 0
Study 11106989 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium (Ti) removable partial dentures
Number of subjects: 38
Study 11106989 — intervention group
Group type: COMPARATOR
Intervention: Cobalt‐chromium (Co‐Cr) removable partial dentures
Number of subjects: 38
Study 9176834 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg zinc
Number of subjects: 372
Study 9176834 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg zinc with micronutrients
Number of subjects: 372
Study 9176834 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients alone
Number of subjects: 372
Study 9176834 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-containing treatments
Number of subjects: 372
Study 7980110 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine
Number of subjects: 24
Study 7980110 — intervention group
Group type: COMPARATOR
Intervention: 3,4-diaminopyridine
Number of subjects: 24
Study 2481787 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 99
Study 2481787 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 99
Study 2481787 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg/day)
Number of subjects: 99
Study 2481787 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepindolol (10 mg/day)
Number of subjects: 99
Study 2481787 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (400 mg/day)
Number of subjects: 99
Study 2481787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 4938432 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole
Number of subjects: 103
Study 4938432 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 103
Study 31014099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 1791
Study 31014099 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 1791
Study 28683729 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 2000
Study 25795285 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (2.5 g twice daily)
Number of subjects: 17
Study 23564065 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 120
Study 23564065 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 120
Study 22473395 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐hMG
Number of subjects: 731
Study 22473395 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH
Number of subjects: 731
Study 22473395 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 731
Study 19201289 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotic Lactobacillus rhamnosus R0011 strain (500 million active cells/tablet twice daily)
Number of subjects: 77
Study 19201289 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo treatment
Number of subjects: 77
Study 17317362 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day of atorvastatin for 16 weeks
Number of subjects: 3086